CAS 71170-82-6: 1,1,1-Triethyl 3-bromo-1,1,1-propanetricarboxylate

Triethyl 3-bromopropane-1,1,1-tricarboxylate (TRI) is a purine that is used as a supplement in the form of its salts. It has been found to be an active compound for the treatment of herpes simplex virus type 1 and 2 (HSV-1 and HSV-2). TRI inhibits viral replication by acting on the viral DNA polymerase and blocking the synthesis of DNA, which prevents viral replication. TRI also inhibits cellular protein synthesis through inhibition of ribonucleotide reductase and guanosine kinase. This compound can also be converted to famciclovir, which is currently FDA approved for the treatment of HSV infections. TRI can be synthesized using a catalytic process or a hydrogenolysis process. Catalytic processes are generally preferred because they are more economical than hydrogenolysis processes; however, both methods produce impurities that must be removed before the desired product can be